FDA Approved: CYRAMZA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for CYRAMZA (ramucirumab) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• Cyramza (ramucirumab)

Snippet

SUPPL AP for CYRAMZA (RAMUCIRUMAB)